Table 1.
Clinical characteristics of 188 patients with samples of BM plasma analyzed for cytokine content with 11-plex.
| MDS low risk group | |
|---|---|
| number of patients | 94 |
| number of samples | 125 |
| number of patients with multiple BM aspirations | 31 |
| patient age at BM aspiration (years), median (range) | 72 (46-86) |
| males/females | 54 / 71 |
| Sample distribution according to WHO 2008 | |
| MDS 5q | 23 |
| RCMD | 56 |
| RARS | 1 |
| MDS RA | 1 |
| MDS RN | 3 |
| RAEB I | 31 |
| CMML I | 7 |
| MDS/MPN-u | 3 |
| IPSS risk group | |
| low | 58 |
| intermediate I | 67 |
| intermediate II | 0 |
| high | 0 |
| red cells transfusion requiring, n (%) | 84 (67.2%) |
| co-morbidities | |
| diabetes mellitus | 33 |
| other inflammatory diseases | 34 |
| psoriasis | 3 |
| asthma | 3 |
| chronic gastritis | 1 |
| rheumatoid arthritis | 12 |
| ongoing treatment of bladder carcinoma | 2 |
| lupus | 2 |
| MRSA | 1 |
| gout | 3 |
| renal insufficiency | 10 |
| metabolic syndrome | 1 |
| MDS high risk group and AML | |
| number of patients | 94 |
| number of samples | 140 |
| number of patients with multiple BM aspirations | 46 |
| patient age at BM aspiration (years), median (range) | 72.5 (55-86) |
| males/females | 68 / 72 |
| Sample distribution according to WHO 2008 | |
| RCMD | 3 |
| RARS | 1 |
| RAEB I | 12 |
| RAEB II | 79 |
| CMML I | 5 |
| CMML II | 6 |
| AML < 30% MB* | 28 |
| AML > 30% MB | 4 |
| IPSS risk group | |
| low | 0 |
| intermediate I | 0 |
| intermediate II | 67 |
| high | 35 |
| not applicable | 38 |
| red cells transfusion requiring, n (%) | 77 (55%) |
| co-morbidities | |
| diabetes mellitus | 28 |
| other inflammatory diseases | 18 |
| hepatitis C | 1 |
| rheumatoid arthritis | 5 |
| Sweet syndrome | 1 |
| renal insufficiency | 14 |